Rx Extended-Release Guaifenesin Must Exit Market By November, FDA Says
This article was originally published in The Tan Sheet
Executive Summary
Single-ingredient, extended-release prescription guaifenesin products must be removed from the market by the end of November if they have not been approved by FDA, the agency states in Feb. 25 letters to 66 marketers and distributors of the drugs
You may also be interested in...
Adams May Cough Up Humibid As Product Confusion Congests Sales
Adams Respiratory Therapeutics is considering whether to stop offering its Humibid 1,200 mg guaifenesin product, which it markets voluntarily behind the counter, as it launches an over-the-counter version of the same product under the name Maximum Strength Mucinex
FDA Maps Pathways To Compliance At Unapproved Drugs Workshop
FDA plans to increase enforcement actions against marketed unapproved drugs in the coming year, but hopes to cooperate with firms willing to come to the table seeking approval for currently unapproved products
Adams’ Suit Could Delay ANDA For URL/Mutual’s Mucinex Generic
A lawsuit filed by Adams Respiratory Therapeutics could bring a stay of up to 30 months on FDA's approval of Mutual Pharmaceuticals and United Research Laboratories' application for a generic version of Adams' Mucinex extended-release expectorant product